Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Common Equity (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Common Equity for 14 consecutive years, with $207.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 35.0% year-over-year to $207.2 million, compared with a TTM value of $207.2 million through Dec 2025, down 35.0%, and an annual FY2025 reading of $207.2 million, down 35.0% over the prior year.
  • Common Equity was $207.2 million for Q4 2025 at Fate Therapeutics, down from $234.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $790.1 million in Q1 2021 and bottomed at $207.2 million in Q4 2025.
  • Average Common Equity over 5 years is $467.4 million, with a median of $431.9 million recorded in 2023.
  • The sharpest move saw Common Equity soared 260.42% in 2021, then crashed 35.4% in 2025.
  • Year by year, Common Equity stood at $678.8 million in 2021, then decreased by 28.71% to $483.9 million in 2022, then dropped by 23.87% to $368.4 million in 2023, then decreased by 13.49% to $318.7 million in 2024, then crashed by 35.0% to $207.2 million in 2025.
  • Business Quant data shows Common Equity for FATE at $207.2 million in Q4 2025, $234.1 million in Q3 2025, and $261.4 million in Q2 2025.